U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C16H20N6
Molecular Weight 296.3702
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BATELAPINE

SMILES

CN1CCN(CC1)C2=NC3=C(CC4=NC(C)=NN24)C=CC=C3

InChI

InChIKey=PUHMYHQVPODHCZ-UHFFFAOYSA-N
InChI=1S/C16H20N6/c1-12-17-15-11-13-5-3-4-6-14(13)18-16(22(15)19-12)21-9-7-20(2)8-10-21/h3-6H,7-11H2,1-2H3

HIDE SMILES / InChI
Molecular Formula C16H20N6
Molecular Weight 296.3702
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Batelapine (or CGS 13429), an antipsychotic drug, that was undergoing preclinical development, but the further studied were discontinued

Originator

Novartis
177

Approval Year

Unknown
149,124

PubMed

Patents

20070116729
163

Sample Use Guides

In Vivo Use Guide
single oral ascending doses ranging from 0.1 to 10 mg in healthy male voluntee
Route of Administration: Oral
Substance Class Chemical
Record UNII
P71TE299SG
Record Status Validated (UNII)
Record Version
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966